Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of an oral dual tyrosine
kinase inhibitor (GW572016) in combination with paclitaxel compared to paclitaxel alone in
first line advanced or metastatic breast cancer.